Drug Trial Radar · NCT06079541
Phase 1 Clinical Study of JMKX003142 Tablets
Last checked: Nov 19, 2026Latest source record: Oct 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
106
Planned (sponsor's estimate)
Start
Jul 6, 2023
Primary completion
Jul 31, 2024
Study completion Mar 30, 2025
Sponsor
- Lead sponsor
- JemincareIndustry
- Sponsor type
- Industry
- Collaborators
- Zhejiang Hangyu Pharmaceutical Co., Ltd.
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of JMKX003142 tablets administered randomly, double-blind, placebo-controlled single and multiple times in healthy adult subjects, as well as the effects of randomized, open, and two cycle crossover foods
Conditions
- Safety and Tolerability
Interventions
JMKX003142 will be administered orallyDrug
oral once
JMKX003142 will be administered orallyDrug
oral once
JMKX003142 will be administered orallyDrug
oral once
Placebo in Cohorts 1 to 7Drug
oral once
Placebo in 3 CohortsDrug
oral once
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of the Adverse Events that are related to the single dose treatmentTime frame: from baseline to Day 18
- Number of the Adverse Events that are related to the multiple dose treatment fromTime frame: from baseline to Day 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.